My last analysis of argenx SE ( ARGX ) followed an on-the-market safety event for its lead product, VYVGART HYTRULO (subcutaneous efgartigimod). The issue, however, seemed more related to how CIDP patients are transitioned from IVIG to VYVGART HYTRULO, rather than just the drug itself. AsAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it exp ...